Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Starling Oncology, Inc.

NASDAQ: STLN · Industrial Applications and Services · 6 alerts · CIK 1799191

Share price
$3.54Close, Nov 16
Market cap
$361M
Shares outstanding
101.99MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Offices & Clinics of Doctors of MedicineSIC 8011

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Starling Oncology, Inc. filings on SEC EDGAR ↗

4:44 PM ET 8-K/A
Investor Presentation

Starling Oncology Investor Presentation

Starling Oncology, Inc. furnished an updated investor presentation as Exhibit 99.1 to be used in upcoming meetings with investors. This filing is an amendment (Form 8-K/A) that supersedes a previous version of the presentation filed earlier the same day.

8:03 AM ET 8-K
Investor Presentation

Starling Oncology Investor Presentation

Starling Oncology, Inc. has prepared a formal investor presentation to be used in upcoming meetings with investors. The presentation, dated November 12, 2026, was furnished as an exhibit to the 8-K filing and includes a discussion of the company's strategy and financial trends.

6:33 PM ET Form 4
Insider Selling

Starling Oncology Insider Jorey Chernett Sells $11.4M of Stock

Jorey Chernett sold 2,851,061 shares of Starling Oncology, Inc. at $3.99 a share, worth $11.4M in total on Nov 6, 2026. Shares held after the trade: 7,809,797 (-26.7%).

Value
$11.4M
Shares
2,851,061
Price
$3.99
Holding change
-26.7%
Trade date
Nov 6, 2026
6:33 PM ET Form 4
Insider Buying

Starling Oncology Insider Jorey Chernett Buys $176K of Stock

Jorey Chernett bought 48,294 shares of Starling Oncology, Inc. at $3.65 a share, worth $176K in total on Nov 9, 2026. Shares held after the trade: 7,858,091 (+0.6%).

Value
$176K
Shares
48,294
Price
$3.65
Holding change
+0.6%
Trade date
Nov 9, 2026
6:03 AM ET 10-Q
Financial Results

Starling Oncology Q3 2026 Results: Net Loss of $15.7M, Loss Narrows

Starling Oncology, Inc. reported a significant revenue increase to $478.5 million for the nine months ended September 30, 2026, driven primarily by growth in its Specialty Pharmacy segment. Despite this growth, the company remains unprofitable with a net loss of $28.0 million for the period and a total stockholders' deficit of $37.4 million.

Key figure
Net loss $15.7M
4:58 PM ET 8-K
Financial Results

Starling Oncology Financial Results

Starling Oncology reported Q3 2026 consolidated revenue of $169.8 million, a 24.3% increase year-over-year, and achieved its second consecutive quarter of positive Adjusted EBITDA at $3.4 million. The company updated its full-year 2026 revenue guidance to $650-$660 million and raised the low end of its Adjusted EBITDA outlook to $4-$6 million.

Term
Q3 2026

“The third quarter of 2026 was another strong quarter for our company, with revenue up 24% year over year and Adjusted EBITDA of $3.4 million, our second consecutive quarter of positive Adjusted EBITDA and above our third quarter outlook of $0.50 million to $1.5 million. Our capitated business continues to deliver growth, with capitated revenue up 40% and MLR performing at expectations. Our Specialty pharmacy business grew 44% year over year, with strong gross margins of 24% for this segment. Starling Nexus, our proprietary provider-focused portal, is now live and available to our network clinicians to support care coordination and evidence-based care on our delegated capitation model. Based on our performance year to date, we are affirming our full-year 2026 guidance, and we believe we are well positioned for continued growth into 2027.”

Daniel Virnich, CEO of Starling

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.